Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-08-26 10:54:14 - browse：39

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Sarepta Duchenne therapy fails to meet primary endpoint in trial

leisure time

WSS

Adam's Take: Intra

How neuroscience research could help beat back brain cancer

Medicare Advantage insurers pressure Biden for bigger payments

Prime Medicine says its gene editing passes test in monkeys

Bill would allow buprenorphine prescription for addiction via telehealth

Pregnancy ages women, but effects reverse after delivery

explore

Wikipedia

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Key Senate panel to consider PBM, drug pricing reform package

Apple is now the first public company to be valued at $3 trillion

Adam's Take: Intra

Novavax promises a turnaround & Lilly roils the obesity market

Key Senate panel to consider PBM, drug pricing reform package

Anesthesiologist group: stop taking Ozempic before surgery

Medicare proceeds with plan to claw back hospital funds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Coloradans with cystic fibrosis could lose access to Trikafta

knowledge

Diabetes management: Digital health tools fall short, study says

With Wegovy coverage, Medicare patients may face high costs

Asbestos ban is immediate, but health effects will linger for decades

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Medicare proceeds with plan to claw back hospital funds

Prime Medicine says its gene editing passes test in monkeys

focus

leisure time

hotspot

leisure time